The firm brings unique experience to tracking, assessing and explaining regulatory and reimbursement policy that affect the biopharmaceutical industry. The company’s goal is to advance mutual understanding among policymakers, business executives and the investment community, in the belief that a deeper understanding of policy leads to better business, and a deeper understanding of business leads to better policy.
Member Sign In:
- Senate Compounding Bill Revised: “Biologics” Given Separate Status; Avastin Re-Packaging Likely Still Permitted May. 15, 2013
- Track and Trace Bill Passes Energy & Commerce; Defeated Amendments Keep It Moving, But Remain Issues for Conference May. 15, 2013
- FDA’s HIV Patient-Input Meeting on June 14: Focus Will Be Untreated Symptoms and Cure Research May. 14, 2013
See More Research Notes